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1  | INTRODUC TION
Cellular senescence is a phenomenon by which replication-compe-
tent cells cease to divide after extensive replication or exposure to 
stress (Hayflick et al., 1965; Childs et al., 2017). Although cellular 
senescence is an important tumor-suppressive mechanism, emerg-
ing evidence demonstrates that the accumulation of senescent cells 
(SnCs) with age and after genotoxic or cytotoxic cancer therapy can 
lead to various age-related diseases and pathological conditions 
(Demaria et al., 2017; Naylor, Baker, & Deursen, 2013). SnCs exert 
their deleterious effects in part via a senescence-associated se-
cretory phenotype (SASP) (Tchkonia, Zhu, Deursen, Campisi, & 
Kirkland, 2013). Therefore, selectively clearing SnCs and suppress-
ing the SASP have emerged as attractive therapeutic strategies to 
extend health span (Baker et al., 2016), treat age-related diseases 
(Baker et al., 2011; Childs et al., 2016; Jeon et al., 2017), and amelio-
rate chemotherapy-induced toxicity (Demaria et al., 2017; He et al., 
2019). However, SnCs are resistant to the induction of programmed 
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Abstract
The accumulation of senescent cells (SnCs) is a causal factor of various age-related 
diseases as well as some of the side effects of chemotherapy. Pharmacological elimi-
nation of SnCs (senolysis) has the potential to be developed into novel therapeutic 
strategies to treat these diseases and pathological conditions. Here we show that 
ubiquitin-specific peptidase 7 (USP7) is a novel target for senolysis because inhibition 
of USP7 with an inhibitor or genetic depletion of USP7 by RNA interference induces 
apoptosis selectively in SnCs. The senolytic activity of USP7 inhibitors is likely at-
tributable in part to the promotion of the human homolog of mouse double min-
ute 2 (MDM2) ubiquitination and degradation by the ubiquitin–proteasome system. 
This degradation increases the levels of p53, which in turn induces the pro-apoptotic 
proteins PUMA, NOXA, and FAS and inhibits the interaction of BCL-XL and BAK to 
selectively induce apoptosis in SnCs. Further, we show that treatment with a USP7 
inhibitor can effectively eliminate SnCs and suppress the senescence-associated se-
cretory phenotype (SASP) induced by doxorubicin in mice. These findings suggest 
that small molecule USP7 inhibitors are novel senolytics that can be exploited to 
reduce chemotherapy-induced toxicities and treat age-related diseases.
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cell death (apoptosis) (Marcotte, Lacelle, & Wang, 2004). The selec-
tive removal of SnCs depends on identifying their Achilles’ heels, 
which can be targeted to selectively kill SnCs. Several senolytic tar-
gets have been identified, resulting in the discovery of a series of 
senolytic agents that can selectively kill SnCs in culture and effec-
tively remove SnCs in mice (Chang et al., 2016; Childs et al., 2017; 
Zhu et al., 2016). Unfortunately, some of these agents exhibit tox-
icities that may prevent their safe use in the clinic, particularly for 
systemic therapy. For example, navitoclax, a selective BCL-2/XL dual 
inhibitor, is a potent senolytic agent but can induce thrombocyto-
penia, an on-target and dose-limiting toxicity that has prevented its 
FDA-approval. Therefore, further studies are needed to identify new 
senolytic targets that can be exploited for the development of safer 
senolytic agents.
p53 is a well-known tumor suppressor that acts as a double-edged 
sword in regulating cellular senescence, aging, and cancer (Johmura 
&	Nakanishi,	2016;	Wu	&	Prives,	2018).	Levels	and	activities	of	p53	
increase when cells enter a presenescent state upon activation of the 
DNA damage response (DDR), which plays an important role in the 
initiation of cellular senescence. However, the levels of p53 decline in 
some cells after they become senescent, sometimes to a level below 
the basal levels of p53 in non-SnCs. This phenomenon was observed 
in keratinocytes (Kim et al., 2015), some human fibroblast cell lines 
(Johmura et al., 2016; Sisoula, Trachana, Patterson, & Gonos, 2011), 
and human prostate epithelial and uroepithelial cells (Schwarze, Shi, 
Fu, Watson, & Jarrard, 2001). These observations suggest that a sus-
tained upregulation of p53 may not be required for the maintenance 
of senescence in some SnCs, probably because they express a high 
level of p16 which provides another barrier to prevent the escape of 
senescence (Beauséjour et al., 2003). However, not all cells reduce 
their p53 expression when they become senescent (Rufini, Tucci, 
Celardo, & Melino, 2013). In addition, even though the levels of p53 
return to the nearly basal levels in some SnCs after the acute DDR, 
a functional fraction of p53 may remain associated with chromatin 
to mediate the maintenance of senescence (Kirschner et al., 2015), 
particularly in cells expressing low levels of p16 (Beauséjour et al., 
2003).
The downregulation of p53 after some cells become senescent 
may be in part attributable to the upregulation of C-terminus of 
Hsp70-interacting protein (CHIP) (Sisoula et al., 2011) and SCFFbxo22 
(Johmura et al., 2016) E3 ligases, which promote p53 ubiquitination 
and proteasome degradation. SCFFbxo22-mediated p53 downregula-
tion may play an important role for the expression of SASP in these 
SnCs, because the expression of SASP depends on the activation 
of	p38-MAPK	and	NF-κB; and p53 can suppress SASP via inhibiting 
p38-MAPK	 activity	 and	 competing	with	NF-κB for transcriptional 
cofactors (Johmura et al., 2016). In addition, the reduction of p53 
in these SnCs may protect them from apoptosis and contribute to 
the accumulation of SnCs and higher prevalence of cancer during 
aging because p53 is one of the most important apoptosis deter-
minants, which can act through transcription-dependent and tran-
scription-independent mechanisms (Fridman & Lowe, 2003). This 
suggestion is in agreement with the finding that several tissues in 
aged mice showed reduced p53 activity (Feng et al., 2007) and accu-
mulation of SnCs (Baker et al., 2016). Therefore, restoration of p53 
activity has the potential to eliminate these SnCs which downreg-
ulate their expression of p53 after they become senescent by in-
ducing apoptosis. This hypothesis is supported by the finding that 
increasing p53 activity by disrupting its interaction with FOXO4 
using an interfering peptide selectively induced apoptosis in some 
cultured SnCs and effectively cleared SnCs in fast aging XpdTTD/TTD 
and naturally aged mice (Baar et al., 2017). However, there remain 
challenges using a peptide as a therapeutics and, again, not all SnCs 
use the same apoptosis-avoiding mechanism. Thus, identifying new 
strategies to selectively kill SnCs by activating p53 will increase pos-
sibilities for extending health span and treating age-related diseases 
and chemotherapy-induced side effects.
p53 can also be activated by inhibiting the interaction between 
MDM2 and p53. The levels and activities of p53 are strongly reg-
ulated primarily by post-transcriptional mechanisms, including 
MDM2-mediated ubiquitination and proteasome degradation (Kruse 
& Gu, 2009). Inhibiting the interaction between MDM2 and p53 can 
increase p53 stability and activity (Moll & Petrenko, 2003). Indeed, 
recent findings show that UBX0101, an inhibitor of MDM2, selec-
tively killed some SnCs in culture and effectively cleared them in 
mice with post-traumatic osteoarthritis (Jeon et al., 2017). Similar 
to other senolytics derived from anticancer targeted agents, MDM2 
inhibitors can cause hematopoietic suppression and gastrointestinal 
toxicity (Tisato, Voltan, Gonelli, Secchiero, & Zauli, 2017). It has yet 
to be determined whether these adverse effects are on-target tox-
icities or off-target side effects. Therefore, MDM2 inhibitors may be 
best for clearing SnCs to treat age-related diseases such as osteoar-
thritis via local administration. It is thus important to find alternative 
strategies to activate p53 without causing severe toxicity but capa-
ble of effectively clearing SnCs systemically.
USP7 plays an important role in regulating p53 activity by deu-
biquitinating MDM2 to protect it from degradation by the ubiquitin–
proteasome system (UPS). Thus, USP7 inhibition can stabilize p53 by 
promoting MDM2 auto-ubiquitination and degradation (Li, Brooks, 
Kon, & Gu, 2004). Inhibition of USP7 has been proven effective in 
killing various cancer cells, in part by activating p53 and inducing 
apoptosis (Chauhan et al., 2012; Fan et al., 2013; Tavana et al., 2016). 
Unlike MDM2 inhibitors, USP7 inhibitors were well tolerated in mice 
at doses that effectively inhibited tumor growth (Chauhan et al., 
2012; Fan et al., 2013; Tavana et al., 2016), suggesting that pharma-
cological inhibition of USP7 may be safer than inhibition of MDM2. 
Therefore, we examined whether USP7 is a novel senolytic target 
and whether inhibition of USP7 by a small molecule can selectively 
kill some SnCs in culture and clear the cells in vivo. Our results show 
that inhibition of USP7 by a small molecule or genetic depletion 
can selectively induce apoptosis in several types of SnCs at least in 
part via restoring p53 activity, which in turn induces the pro-apop-
totic proteins PUMA, NOXA, and FAS and inhibits the interaction 
of BCL-XL and BAK because SnCs are more sensitive to the pertur-
bation of mitochondrial apoptotic pathways than non-SnCs (Chang 
et al., 2016; Yosef et al., 2016; Zhu et al., 2017). Furthermore, we 
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show that treatment with a USP7 inhibitor can effectively eliminate 
SnCs and suppress the SASP induced by doxorubicin in mice with-
out causing changes in blood cell counts and loss of body weight. 
These findings suggest that small molecule USP7 inhibitors are novel 
senolytics that can be exploited to reduce chemotherapy-induced 
toxicities and treat age-related diseases.
2  | RESULTS
2.1 | Inhibiting USP7 activity reduces MDM2 
expression, increases p53 expression, and induces 
apoptosis selectively in SnCs
As shown previously (Sisoula et al., 2011), basal levels of p53 in 
nonsenescent	 WI-38	 human	 fibroblasts	 were	 relatively	 low,	 but	
increased dramatically after exposure to ionizing radiation (IR) 
(Figure 1a). However, when the cells became senescent after ex-
posure to IR, they expressed a significantly lower basal level of 
p53	compared	to	WI-38	non-SnCs	(Figure	1a,	b	and	Figure	S1a,	b).	
Replicative	 senescent	WI-38	 cells	 also	 expressed	 a	 lower	 level	 of	
p53 than non-SnCs (Figure 1b). Moreover, this phenomenon is not 
specific	to	WI-38	cells	because	IMR-90	fibroblasts,	renal	epithelial	
cells (RECs), and human umbilical vein endothelial cells (HUVECs) 
also expressed a significantly lower basal level of p53 when they 
became senescent (Figure S1c). However, the reduced basal levels 
of	 p53	 in	WI-38	 SnCs	were	 unlikely	 attributable	 to	 the	 increased	
expression of MDM2 (Figure 1a, b).
To determine whether USP7 inhibition can selectively kill some 
SnCs via the MDM2-p53 pathway, we examined the effect of 
USP7	 inhibition	on	MDM2	and	p53	 levels	 in	WI-38	non-SnCs	and	
IR-induced SnCs after treatment with different concentrations of 
P5091, a widely used USP7 inhibitor (Chauhan et al., 2012). P5091 
downregulated	 MDM2	 and	 upregulated	 p53	 in	 WI-38	 SnCs	 but	
not	 in	WI-38	 non-SnCs	 (Figure	 1c).	We	 observed	 similar	 findings	
when these cells were treated with another USP7 inhibitor, P22077, 
and in IMR90 cells treated with P5091 (Figure 1c and Figure S1d). 
However,	p53	levels	in	P5091-treated	WI-38	SnCs	remained	slightly	
lower than the basal level of p53 in untreated non-SnCs, suggesting 
that USP7 inhibition only partially restored the basal levels of p53 
in	WI-38	SnCs	and	did	not	dramatically	increase	p53	expression	as	
seen	in	WI-38	cells	after	exposure	to	IR	(Figure	1a,	c).	The	changes	in	
MDM2 and p53 expression in SnCs induced by USP7 inhibition were 
abrogated by suppressing proteasome activity using the inhibitor 
MG132 (Figure 1d). Thus, the changes in MDM2 and p53 expression 
in SnCs induced by USP7 inhibition relied on protein degradation by 
proteasomes.
Next, we examined the effect of USP7 inhibition on cell viability. 
IR-induced	WI-38	SnCs	were	more	sensitive	to	P5091	and	P22077	
than non-SnCs (Figure 2a). Similar findings were observed in repli-
catively	 senescent	WI-38	and	 IMR-90	 fibroblasts,	RECs,	HUVECs,	
and human preadipocytes (PA) induced to senesce by IR or extensive 
replication (Figure S2a–e). The loss of SnC viability after incubation 
with P5091 occurred very rapidly (Figure 2b) and was primarily at-
tributable to apoptosis because SnCs treated with P5091 showed 
significant increases in Annexin V staining (Figure 2c) and cleavage 
of poly(ADP-ribose) polymerase (PARP) (Figure 2d). Further, the 
pan-caspase inhibitor QVD abrogated the effect of P5091 on the 
viability of SnCs (Figure 2e).
To validate the specificity of the effects of USP7 inhibitors on 
SnCs,	we	transfected	WI-38	non-SnC	and	SnC	cells	 induced	by	 IR	
with control or USP7 small interfering RNA (siRNA) to deplete USP7. 
The USP7 siRNA effectively reduced the expression of USP7 in both 
cells (Figure 2f), resulting in a significant reduction in MDM2 expres-
sion. However, consistent with the effects of the USP7 inhibitor, 
USP7 depletion increased p53 expression selectively in SnCs and re-
duced their viability while having no significant effects on non-SnCs 
(Figure 2f). Furthermore, USP7 depletion by siRNA selectively re-
duced	the	viability	of	replicatively	senescent	WI-38,	and	IR-induced	
or replicatively senescent IMR90 cells (Figure S2f and g). These re-
sults confirm that USP7 is a novel senolytic target and inhibition of 
USP7 activity can selectively kill SnCs, probably in part by destabi-
lizing MDM2 and upregulating p53.
2.2 | Inhibition of USP7 activity induces SnC 
apoptosis in part via a p53-dependent manner
To determine whether p53 is required for mediating USP7 inhibition-
induced	apoptosis	in	SnCs,	we	generated	p53	knockout	WI-38	cells	
using CRISPR/cas9 technology (Figure S3a). Knockout p53 had no 
significant effect on the induction of senescence by IR because both 
wild-type	(WT)	and	p53	knockout	WI-38	cells	became	permanently	
growth arrested (i.e., inability to incorporate bromodeoxyuridine), 
expressed increased levels of p16 and p21 and stained positive for 
senescence-associated β-galactosidase (SA-β-gal) after exposure to 
IR (Figure S3b–d). These results suggest that p53 is dispensable for 
the induction of cellular senescence by IR, as reported (Nair, Bagheri, 
& Saini, 2015). However, senescent p53 knockout cells were re-
sistant to apoptosis and cell death caused by USP7 inhibition with 
P5091	(Figure	3a,	b).	In	contrast,	wild-type	WI-38	SnCs	underwent	
apoptosis after treatment with P5091. This result confirms that 
USP7 inhibition at least in part depends on p53 for the selective in-
duction of SnC apoptosis.
p53 is a transcriptional factor that induces apoptosis primarily by 
inducing the expression of pro-apoptotic genes, including BBC3 (en-
coding PUMA), PMAIP1 (encoding NOXA), and FAS (Fridman & Lowe, 
2003). In addition, p53 can also induce apoptosis in a transcription-in-
dependent manner by translocating into mitochondria to interfere 
with the interaction between anti-apoptotic BCL-family proteins and 
pro-apoptotic proteins (Speidel, 2010). Therefore, we performed 
p53 immunofluorescent staining to determine p53 distribution in 
non-SnCs and SnCs with or without P5091 treatment (Figure 3c and 
Figure S3e). The specificity of the staining was validated using p53 
knockout cells (Figure S3e). As expected, p53 staining was signifi-
cantly lower in SnCs than non-SnCs, which was restored after P5091 
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treatment. In P5091-treated SnCs, some p53 staining was located in 
nuclei but the majority of the staining appeared to be in cytoplasm 
in association with mitochondria (Figure 3c and Figure S3e). These 
findings were confirmed by Western blotting analysis using SnC cy-
toplasmic, mitochondrial, and nuclear protein lysates (Figure S3f).
To determine whether p53 mediates USP7 inhibition-induced 
SnC apoptosis by upregulating pro-apoptotic genes, we compared 
BBC3, PMAIP1, and FAS mRNA levels in non-SnCs and IR-induced 
SnCs with or without P5091 treatment. Untreated SnCs expressed 
significantly lower levels of BBC3 mRNA than non-SnCs. USP7 inhi-
bition had no significant effect on the levels of BBC3, PMAIP1, and 
FAS mRNA in non-SnCs, but slightly elevated BBC3 mRNA in SnCs 
(Figure 3d). Although the expression of PMAIP1 and FAS mRNA was 
not reduced in SnCs, their expression was selectively elevated in SnCs 
after P5091 treatment. A similar change in SnC expression of PUMA, 
NOXA, and FAS at the protein level was observed by Western blot-
ting analysis (Figure 3e). Moreover, these changes correlated with 
the levels of p53, indicating that USP7 inhibition can partially restore 
the expression of p53 and its downstream pro-apoptotic proteins in 
SnCs. These findings suggest that increased p53 transcriptional ac-
tivity may be in part responsible for the induction of SnC apoptosis 
by USP7 inhibition.
In contrast, P5091 increased the expression of MDM2 mRNA 
but reduced the expression of MDM2 protein in SnCs (Figure 3d, e), 
which was abrogated by the pretreatment of the cells with the pro-
teasome inhibitor MG132 (Figure 1c). These findings are in agree-
ment with our suggestion that USP7 inhibition upregulates p53 
expression at least in part via promoting MDM2 proteasome degra-
dation. However, the expression of p21 mRNA in SnCs was elevated 
in comparison with non-SnCs and its expression was not affected 
by P5091 treatment (Figure S3g). These findings suggest that p21 
mRNA expression in SnCs can be regulated in a p53-independent 
manner, which is in agreement with the findings reported previously 
(Aliouat-Denis et al., 2005).
Next, we examined whether USP7 inhibition can promote p53 
interaction with mitochondrial anti-apoptotic BCL-family proteins to 
release pro-apoptotic proteins for the induction of SnC apoptosis 
by immunoprecipitation (Figure 3f-i). p53 complexed with BAK, but 
to a lesser degree to BAX, in both non-SnCs and SnCs, regardless 
of whether the cells were treated with P5091 (Figure 3f). Slightly 
more p53 complexed with BCL-XL in SnCs than non-SnCs without 
P5091 treatment. After P5091 treatment, the p53-BCL-XL interac-
tion increased further in SnCs but decreased slightly in non-SnCs. 
Importantly, P5091 selectively reduced the interaction between 
BCL-XL and BAK in SnCs but not in non-SnCs (Figure 3g). However, 
P5091 had no significant effect on the interaction between BCL-2 
and p53, nor on the interactions between BCL-2 and BAX or BAK 
(Figure 3h and i).
F I G U R E  1   Inhibition of USP7 activity selectively downregulates MDM2 expression and partially restores p53 expression in senescent 
cells	(SnCs).	(a)	Western	blotting	analysis	of	p53,	MDM2	p21,	and	USP7	protein	levels	in	nonradiated	(non-IR)	and	radiated	WI-38	fibroblasts	
at indicated time points. Representative images of Western blots are shown. (b) Western blotting analysis of p53, MDM2, and USP7 protein 
levels	in	nonsenescent	(non-SnC)	and	senescent	(SnC)	WI-38	fibroblasts	induced	to	senescence	by	replicative	exhaustion	(REP-SnC)	or	
ionizing radiation (IR-SnC). Representative images of Western blots are shown in the left panel, and fold changes in p53 expression are 
presented in the right panel as mean ± SEM of 3 independent experiments with non-SnC values set at 1. **p < .01 and ***p < .001. (c) Effect 
of	USP7	inhibition	by	P5091	or	P22077	on	p53,	MDM2	and	USP7	protein	levels	in	non-SnC	and	IR-SnC	WI-38	cells	after	the	cells	were	
treated with P5091 or P22077 (15 µM) for 72 hr. Representative images of Western blots are shown in the left panel, and fold changes in 
p53 and MDM2 levels relative to vehicle-treated non-SnC are presented in the right panel as mean ± SEM of 4 independent experiments. 
*p < .05 and **p < .01. (d) Proteasome inhibition by MG132 abrogated the effects of P5091 on MDM2 and p53 protein levels in IR-SnCs. IR-
SnCs were pretreated with MG132 for 1 hr and then with P5091 for 72 hr. Representative images of Western blots are shown
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These findings suggest that USP7 inhibition selectively induces 
SnC apoptosis at least in part by increasing p53 translocation to mi-
tochondria and its interaction with BCL-XL, since SnCs are more de-
pendent on BCL-2 family proteins for survival compared to non-SnCs 
(Chang et al., 2016; Yosef et al., 2016; Zhu et al., 2016). In addition, 
we predict that USP7 inhibition may sensitize SnCs to apoptosis via 
BCL-2/XL inhibition. Indeed, compared to non-SnCs, SnCs have more 
mitochondria (Figure S4a) and higher levels of BCL-XL and BCL-2 
(Figure S4b and c), and the combination of P5091 and ABT263, a 
BCL-2/XL inhibitor, was more effective in killing SnCs than either 
agent alone (Figure S4d).
2.3 | USP7 inhibition eliminates SnCs and 
reduces the SASP induced by doxorubicin in mice
We used p16-3MR mice treated with doxorubicin (DOX) to deter-
mine whether USP7 inhibition could effectively eliminate SnCs in 
vivo (Figure 4a). Treatment with a chemotherapeutic drug such 
as DOX induces cellular senescence in mice, which contributes to 
chemotherapy-induced toxicities in part due to the SASP (Demaria 
et al., 2017). As shown in our previous study (Demaria et al., 2017), 
p16-3MR mice exhibited significant increases in SnC accumulation 
after DOX treatment based on bioluminescence imaging (Figure 4b), 
which was confirmed by analyzing Cdkn2a mRNA expression in the 
kidney, fat, and lungs using qPCR (Figure 4c). Furthermore, kid-
neys from DOX-treated mice expressed increased levels of mRNAs 
encoding various SASP factors, including IL-1α, IL-1β, IL-6, and 
RANKL compared to vehicle-treated mice (Figure 4d). Treatment 
with the USP7 inhibitor P5091 not only almost completely elimi-
nated SnCs but also abrogated DOX-induced increase in the levels 
of Il1α, Il1β, Il6, and Tnfsf11 mRNAs (Figure 4d). These findings dem-
onstrate that P5091 effectively cleared SnCs induced by DOX in 
vivo. Importantly, mice treated with P5091 for 14 days exhibited no 
significant changes in body weight and no reduction in the number 
of white blood cells, red blood cells, platelets, and neutrophils and 
the level of hemoglobin (Figure S5). These results suggest that USP7 
inhibitors could be safer than MDM2 inhibitors for senolysis.
3  | DISCUSSION
Downregulation of p53 has been identified as one of the mecha-
nisms by which some SnCs gain resistance to apoptosis (Chaturvedi, 
Qin, Stennett, Choubey, & Nickoloff, 2004). The downregulation is 
not	due	to	an	increased	expression	of	MDM2	as	seen	in	WI-38	SnCs,	
but may be attributable to an increased expression of F-Box Protein 
22 (Fbxo22) and SCFFbxo22-KDM4A E3 ligase activity, which can in-
duce p53 ubiquitination and degradation (Johmura et al., 2016). In 
addition, some cells can downregulate p53 expression at the tran-
scriptional level after they become senescent (Kim et al., 2015). Here 
we report the discovery of a novel approach to selectively increase 
p53 expression and induce apoptosis in SnCs via USP7 inhibition. 
The mechanism by which USP7 inhibition increases p53 expression 
F I G U R E  2   Inhibition of USP7 activity selectively induces apoptosis in SnCs. (a) Effect of USP7 inhibitors on cell viability of non-SnC 
and	IR-SnC	WI-38	cells.	Viability	was	determined	after	cells	were	treated	with	the	indicated	concentrations	of	P5091	or	P22077	for	72	hr.	
Data are presented as mean ± SEM (n	=	3).	(b)	P5091	induces	cell	death	in	IR-SnC	in	a	time-dependent	manner.	IR-SnC	WI-38	cells	were	
treated with 15 µM P5091, and cell viability was determined at indicated time points. Data are presented as mean ± SEM (n = 4). (c) P5091 
selectively induces apoptosis in IR-SnC in a dose-dependent manner. Apoptosis was determined after cells were treated with P5091 for 
72 hr by Annexin V-Alexa Fluor 647 and PI staining and flow cytometry. Representative flow cytometric plots are shown in the left panel, 
and percentages of apoptotic cells (Annexin V+ and Annexin V+/PI+ cells) are presented in the right panel as mean ± SEM of 3 independent 
experiments. *p < .05 and ****p < .0001. (d) Representative images of Western blots of PARP and cleaved PARP (cPARP) in non-SnC and 
IR-SnC	WI-38	cells	72	hr	after	treatment	with	P5091.	(e)	Percentages	of	apoptotic	cells	in	IR-SnC	WI-38	cells	after	pretreatment	with	the	
pan-caspase inhibitor QVD for 4 hr, and then with or without P5091 for 24 hr. Data are presented as mean ± SEM (n = 3). ****p < .0001. 
(f) Knockdown of USP7 expression by siRNA reduces MDM2, upregulates p53, and induces apoptosis in IR-SnCs. USP7, p53, and MDM2 
protein	levels	were	determined	after	transfection	with	control	siRNA	(Ctr),	USP7	siRNA-1	(si1),	or	USP7	siRNA-2	(si2)	for	48	hr.	Cell	viability	
in	non-SnC	and	IR-SnC	WI-38	cells	was	determined	4	d	after	transfection.	Representative	images	of	Western	blots	are	shown	in	the	left	
panel, and percentages of viable cells are presented in the right panel as mean ± SEM of 3 independent experiments. **p < .01
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is likely attributable in part to the reduction of MDM2 expression as 
USP7 stabilizes MDM2 via deubiquitinating MDM2 (Li et al., 2004). 
This hypothesis is supported by our finding that proteasome inhibi-
tion with MG132 abrogated USP7 inhibition-induced downregula-
tion of MDM2 and upregulation of p53 in SnCs. Interestingly, USP7 
inhibition had no significant effect on the expression of MDM2 and 
p53, nor did it significantly increase apoptosis in non-SnCs. Thus, 
USP7 is a new senolytic target and USP7 inhibitors are novel seno-
lytic agents at least for some SnCs which downregulate their expres-
sion of p53 after they become senescent.
However, USP7 has multiple targets (Pozhidaeva & Bezsonova, 
2019) and p53 knockout only attenuated but did not abrogate USP7 
inhibition-induced SnC apoptosis. Therefore, it is possible that USP7 
inhibition may induce SnC apoptosis not only via a p53-dependent 
manner but also through a p53-independent mechanism. It has 
been shown previously that USP7 inhibition can induce apoptosis 
in various cancer cells via restoration of PTEN nuclear pool (Carrà 
et al., 2017), inhibition of Wnt signaling (An et al., 2017), and induc-
tion of oxidative and endoplasmic reticulum stress (Lee et al., 2016). 
However, whether any of these mechanisms contribute to USP7 in-
hibition-induced SnC apoptosis has yet to be determined.
The results from our studies also suggest that p53 may medi-
ate USP7 inhibition-induced SnC apoptosis via both transcriptional 
and post-transcriptional mechanisms. First, we found that upregu-
lation of p53 expression in SnCs after USP7 inhibition with P5091 
treatment increased the expression of several pro-apoptotic pro-
tein genes including PUMA, NOXA, and FAS mRNA. In addition, we 
showed that p53 induced by USP7 inhibition in SnCs localized par-
tially to mitochondria, where it might induce SnC apoptosis by inter-
acting with BCL-XL and displacing BAK. This finding is in agreement 
with the observation that inhibiting the interaction between FOXO4 
and p53 by a FOXO4-D-retro-inverso (DRI) peptide selectively in-
duced apoptosis in SnCs in a p53 transcriptional activity-indepen-
dent manner by promoting p53 translocation from the nuclei to the 
mitochondria (Baar et al., 2017). This mechanism may contribute to 
the selective induction of apoptosis in SnCs by USP7 inhibition be-
cause studies from our groups and others show that SnCs are more 
dependent on BCL-XL for survival (Chang et al., 2016; Yosef et al., 
F I G U R E  3   Inhibition of USP7 activity selectively induces apoptosis in SnCs partially through a p53-dependent manner. (a) p53 knockout 
(p53	KO)	attenuates	P5091-induced	apoptosis	in	IR-SnC	WI-38	cells.	Apoptosis	in	wild-type	(WT)	and	p53	KO	IR-SnC	WI-38	cells	was	
determined after treatment with vehicle or P5091 (15 µM) for 72 hr by Annexin V-Alexa Fluor 647 and PI staining and flow cytometry. 
Representative flow cytometric plots are shown in the left panel, and percentages of apoptotic cells (Annexin V+ and Annexin V+/PI+ 
cells) are presented in the right panel as mean ± SEM of 3 independent experiments. *p < .05 and ***p < .001. (b) p53 knockout (p53 KO) 
attenuates	the	senolytic	effect	of	P5091	on	IR-SnC	WI-38	cells.	Cell	viability	in	wild-type	(WT)	and	p53	KO	IR-SnC	was	determined	after	
they were treated with vehicle or P5091 (15 µM) for 72 hr by PI staining using flow cytometry. Percentages of viable cells (PI- cells) are 
presented as mean ± SEM (n = 4). **p < .01 and ***p < .001. (c) Representative images of p53 immunofluorescent staining (green) in non-
SnC	and	IR-SnC	WI-38	cells	after	the	cells	were	treated	with	or	without	P5091	for	16	hr.	The	mitochondria	and	nucleus	were	stained	with	
MitoTracker Red CMXRos (red) and DAPI (blue), respectively. (d) BBC3, PMAIP1, FAS, and MDM2	mRNA	levels	in	non-SnC	and	IR-SnC	WI-38	
cells after treatment with P5091 for 9 hr were measured by quantitative PCR (qPCR). Data are presented as mean ± SEM (n = 3) of fold 
changes. *p < .05, ***p < .001, and ****p < .0001. (e) Representative images of Western blots of p53, MDM2, PUMA, NOXA, and FAS in non-
SnC	and	IR-SnC	WI-38	cells	after	treatment	with	or	without	P5091	for	72	hr.	(f)	Analysis	of	the	interaction	of	p53	with	BCL-XL,	BCL-2,	BAK,	
and	BAX	in	non-SnC	and	IR-SnC	WI-38	cells	after	treatment	with	vehicle	or	P5091	for	16	hr	by	immunoprecipitation	(IP)	and	immunoblotting	
(IB).	(g)	Co-IP	of	BCL-XL	with	BAK	and	BAX	in	non-SnC	and	IR-SnC	WI-38	cells	with	or	without	P5091	treatment	for	16	hr.	(h)	Co-IP	of	BCL-2	
with	BAK	and	BAX	in	non-SnC	and	IR-SnC	WI-38	cells	with	or	without	P5091	treatment	for	16	hr.	(i)	Levels	of	p53,	BCL-XL,	BCL-2,	BAX,	and	
BAK in the lysates used for the IP experiments presented in (f-h)
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2016; Zhu et al., 2016). Therefore, a combination treatment with the 
USP7 inhibitor P5091 and BCL-XL inhibitor ABT263 could synergis-
tically kill SnCs, as shown in our studies.
Using a small molecule USP7 inhibitor to selectively upregulate 
p53 and induce apoptosis in SnCs may be a good alternative to the 
use of FOXO4-DRI and MDM2 small molecule inhibitors as the 
use of peptides as a therapeutic remains a challenge, and MDM2 
inhibitors can be toxic to the hematopoietic and gastrointestinal 
systems (Tisato et al., 2017). Treatment of mice with the USP7 
inhibitor P5091 effectively eliminated SnCs and reduced the ex-
pression of SASP factors induced by DOX without affecting body 
weight or blood cell counts. However, most known USP7 inhibi-
tors, including P5091, are still in early development and not ready 
for extensive studies to examine senolytic activity or toxicity in 
vivo. With an increasing interest and effort in the development 
of USP7 inhibitors for cancer therapy (Chauhan et al., 2012; Fan 
et al., 2013; Tavana et al., 2016), more specific and potent USP7 
inhibitors may become available in the near future. However, 
USP7 is expressed in many tissues and regulates other substrates 
that	 have	 different	 physiological	 functions	 (Zhou	 et	 al.,	 2018).	
Therefore, it remains to be determined whether USP7 inhibitors 
can be safely used to extend health span and treat age-related 
diseases, particularly because older people are more susceptible 
to adverse drug effects than younger individuals. Since USP7 in-
hibitors	are	developed	primarily	for	oncology	(Zhou	et	al.,	2018),	
a more viable approach to use USP7 inhibitors as senolytic agents 
may be to clear SnCs induced by chemotherapy because such cells 
can contribute to chemotherapy-induced toxicity and promote 
tumor relapse and metastasis in part via the SASP. This suggestion 
is supported by our finding that treatment of mice with the USP7 
inhibitor P5091 effectively eliminated SnCs and reduced the ex-
pression of SASP factors caused by DOX.
F I G U R E  4   Treatment with the USP7 inhibitor P5091 effectively eliminates SnCs and reduces expression of senescence-associated 
secretory phenotype (SASP) factors induced by doxorubicin (DOX) in mice. (a) Experimental design. CBC, complete blood count. (b) A 
representative bioluminescence image of p16-3MR mice after treatment with vehicle (VEH), DOX or DOX plus P5091 is shown in the left 
panel and the relative intensities of luminescence on day 12 and 19 are presented in the right panel as mean ± SEM (n = 3 mice/group). (c) 
The levels of p16 mRNA in the kidney, inguinal fat, and lungs and (d) the levels of SASP factors Il1α, Il1β, Il6, and Tnfsf11 mRNA in the kidney 
from vehicle (VEH), DOX,or DOX plus P5091-treated mice were quantified by qPCR and are presented as mean ± SEM of fold changes in 
comparison with those from vehicle-treated mice (n = 6). a, p < .05 and b, p < .05 versus. VEH and DOX group, respectively
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In conclusion, we reveal that USP7 is a novel senolytic target, and 
USP7 inhibition can selectively kill some SnCs with p53 downregula-
tion in vitro and clear SnCs induced by chemotherapy in mice in part 
by destabilizing MDM2 to increase p53 expression. However, not 
all cells reduce their p53 expression when they become senescent 
(Rufini et al., 2013). It has yet to determine whether SnCs without 
p53 downregulation are also sensitive to USP7 inhibition-induced 
apoptosis and whether USP7 inhibitors can be used as a broad-spec-
trum senolytic agent.
4  | E XPERIMENTAL PROCEDURES
4.1 | Cell culture and induction of senescence
Human	WI-38	 (catalog	 no.	 CCL-75)	 and	 IMR-90	 (catalog	 no.	 CCL-
186)	 fibroblasts,	 HUVEC	 (catalog	 no.	 CRL-1730),	 REC	 (catalog	 no.	
PCS-400-012, REC), and PA cells (catalog no. PCS-210–010) were 
purchased from American Type Culture Collection (ATCC, Manassas, 
VA, USA). Cells were cultured as described (Li et al. 2019). We consid-
ered	cells	at	low	passage	(WI-38	and	IMR-90	<	25	passages;	HUVEC	
and REC < 10 passages; PA < 4 passages) as non-SnCs. These non-
SnCs used in our study were healthy and subconfluent. For exam-
ple,	WI-38	non-SnCs	expressed	low	levels	of	p16	(CDKN2a)	and	p21	
(CDKN1a) mRNA and were capable of proliferating and synthesizing 
DNA (positive for BrdU staining) (Figure S1a and b). Senescence in-
duction was done as previously reported (Li et al., 2019).
4.2 | p53 knockout by CRISPR/Cas9 
genomic editing
Two different sgRNAs targeting human p53 were cloned into the 
lentiCRISPR v2 vector (a gift from Feng Zhang; Addgene plasmid # 
52,961) (Sanjana, Shalem, & Zhang, 2014). Packaging 293T cells were 
transfected with sgRNAs or negative controls (nontargeting sgRNA-
NC) and helper vectors (pMD2.G and psPAX2; Addgene plasmid 
#s12259 and 12,260) using Lipofectamine 2000 reagent. Medium 
containing	viral	particles	and	8	μg/mL polybrene was used to infect 
cells. Infected cells were selected in medium containing 2 μg/mL 
puromycin. Reagents used are provided in Table S1. The guide se-
quences are provided in Table S2.
4.3 | USP7 gene silencing
Non-SnCs and IR-SnCs were transfected with a USP7 siRNA oligo-
nucleotide duplex (siRNA ID: s15440 and s15441, Thermo Fisher 
Scientific, Waltham, MA, USA) using Lipofectamine RNAiMax (Table 
S1). Generally, siRNA and Lipofectamine RNAiMax were individually 
diluted in Opti-MEM medium, gently mixed, incubated for 20 min 
at room temperature, and then added to cells at a final concentra-
tion of 50 nM siRNA. The effectiveness of siRNA knockdown was 
determined on days 2 and 5 after transfection by measuring the level 
of USP7 protein by Western blotting.
4.4 | Cell viability assay and EC50 calculation
Cell viability was measured as previously described (Chang et al., 
2016; Li et al., 2019), or by CellTiter-Glo® Luminescent Cell Viability 
Assay kit (Table S1) as per the manufacturer's instructions. Dose re-
sponses were determined for each compound, and half-maximal ef-
fective concentrations (EC50 values) were calculated using GraphPad 
Prism 6 software.
4.5 | Apoptosis assay
Apoptosis assay was done as previously reported (Li et al., 2019). 
Reagents for this assay are provided in Table S1.
4.6 | Western blotting
Western blotting was done as previously reported (Li et al., 2019). 
All regents and primary antibodies used are provided in Tables S1 
and S3.
4.7 | Cell fraction isolation and co-
immunoprecipitation
Cell fractions were isolated using the Cell Fractionation Kit with 
minor modifications. In order to concentrate mitochondrial and 
nuclear proteins, less volume of Buffer C (half of Buffer B) was 
used to re-suspend the pellet after isolating cytoplasmic protein. 
GAPDH, Cox IV, and PARP were used as markers for cytoplasmic, 
mitochondrial, and nuclear fractions, respectively. For co-immuno-
precipitation (Co-IP), total protein was extracted using the Pierce 
IP Lysis Buffer supplemented with 1% Protease Inhibitor Cocktail 
and 1% Phosphatase Inhibitor Cocktail. 500–1,000 µg protein was 
incubated with anti-p53, anti-BCL-XL, BCL-2, or nonspecific anti-
bodies overnight. Antibodies were crossed-linked to Pierce Protein 
A/G Magnetic Beads for 2 hr. After washing 3 times with IP lysis 
buffer, proteins were eluted with 50 µl IP lysis buffer and 50 µl 
loading buffer. The eluates were boiled and analyzed by Western 
blotting. All regents and antibodies are provided in Tables S1 and 
S3.
4.8 | RNA extraction and real-time PCR analysis
Total RNA extraction was done as previously reported (Li et al., 
2019). Real-time PCR was performed using specific Taqman probes 
(Table S4) and the TaqMan Fast Advanced Master Mix. All reagents 
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and kits are provided in Table S1. All experiments were performed in 
2–3 replicates. Cell data were normalized to GAPDH, and tissue data 
were normalized to Hprt.
4.9 | Immunofluorescence
Non-SnCs and IR-SnCs were seeded in glass bottom microwell 
dishes, treated with 15 µM P5091 overnight, then incubated with 
150 nM MitoTracker Red CMXRos in culture medium per the manu-
facturer's instructions. After blocking with 3% BSA, anti-p53 anti-
body was added (1:500 dilution) and incubated at room temperature 
for	1	hr	followed	by	incubation	with	anti-mouse	IgG-Alexa	Fluo488	
(1:2000 dilution) for 30 min at room temperature. After removing 
antibodies, cells were rinsed with PBS 3 times. Nuclei were stained 
using 0.25 µg/ml DAPI for 5 min at room temperature. Cells were 
rinsed with PBS 3 times and mounted with PBS and 1% BSA. Cells 
were viewed and photographed immediately using an Axioplan mi-
croscope (Carl Zeiss Inc, Jena, Germany) equipped with a 100 W 
mercury light source. Images were processed using Image-Pro Plus 
software (Media Cybernetics, Rockville, Maryland, USA). All regents 
and antibodies used are provided in Tables S1 and S3.
4.10 | Senescence-associated β-galactosidase (SA-β-
gal) assay and BrDU Staining
SA-β-gal activity was determined using the β-Galactosidase Staining 
Kit (Table S1), and DNA synthesis was detected using the Click-iT™ 
Plus	EdU	Alexa	Fluor™	488	Imaging	Kit	(Table	S1)	according	to	the	
manufacturer's instructions.
4.11 | Mice
Young (2 months old) p16-3MR mice were bred at the University 
of Florida (UF) animal facility certified by the Association for 
the Assessment and Accreditation of Laboratory Animal Care 
International (AAALAC). Mice were randomly assigned to 5 per 
cage, housed at the facility and received food and water ad libitum. 
Where indicated, p16-3MR mice were injected i.p. once with 10 mg/
kg DOX in PBS, then, 5 days later, given daily i.p. injections of vehicle 
(4%	NMP,	3%	Tween-80	and	20%	PEG400	in	Milli-Q	water)	or	P5091	
(15 mg/kg) for 14 days. Body weight was measured every two days. 
In vivo bioluminescence was performed as described (Chang et al., 
2016). One day after the second bioluminescence imaging, blood 
samples were collected for complete blood count (CBC) analysis using 
a HEMAVET® analyzer (Drew Scientific, Inc., Oxford, CT, USA). Mice 
were euthanized by CO2 suffocation followed by cervical dislocation. 
Tissues were harvested and immediately frozen in liquid nitrogen and 
stored	at	−80°C	until	processing.	The	Institutional	Animal	Care	and	
Use Committees of UF approved all experimental procedures used 
in this study.
4.12 | Statistical analysis
Data are expressed as means ± SEM and analyzed by analysis of vari-
ance (ANOVA) using Graphpad Prism from GraphPad Software (San 
Diego, CA, USA). Post hoc comparisons were performed between 
group means, comparisons made using Newman–Keuls or Tukey's 
multiple comparisons test. Comparisons were made by Student's t 
test when comparing two experimental groups. p < .05 was consid-
ered significant.
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